Universitaetsklinikum Essen AöR

At Universitaetsklinikum Essen AöR, a major share of research focuses on neoplasms and blood cancers, with studies spanning acute leukemia, lymphoma, multiple myeloma, breast cancer, lung cancer, and prostate cancer. The trials are designed to test new treatments, refine biomarker-guided care, and compare treatment strategies for patients with advanced or hard-to-treat disease.

• Targeted and immune-based approaches for advanced solid tumors and metastatic cancers
• New treatment options for leukemia, lymphoma, and myelodysplastic syndromes
• Therapy optimization in breast, lung, colorectal, ovarian, and prostate cancers

This research also includes efforts to improve outcomes after standard therapy, support personalized treatment selection, and evaluate whether newer combinations can offer better disease control.

The site also runs trials in immune system diseases and chronic inflammatory conditions such as multiple sclerosis, systemic lupus erythematosus, Crohn’s disease, ulcerative colitis, myasthenia gravis, and hidradenitis suppurativa. These studies aim to improve symptom control, reduce disease activity, and assess whether new therapies can offer better long-term management.

• Therapy development for autoimmune and inflammatory disorders
• Studies in relapsing and progressive neurological immune disease
• Evaluation of treatment effectiveness in chronic gut, skin, and neuromuscular inflammation

Research in this area reflects a strong interest in understanding immune-driven disease processes and finding more effective, better-tolerated treatment options.

Clinical trials at Department of Anesthesiology and Intensive Care and related teams include work in nervous system diseases, especially multiple sclerosis, migraine, epilepsy, glioblastoma, medulloblastoma, and other brain tumors. The research is focused on testing new therapies, improving disease control, and supporting better outcomes in both adult and pediatric patients.

• New treatments for relapsing and progressive neurological disease
• Studies in primary and recurrent brain tumors
• Trials aimed at better migraine prevention and seizure management

The portfolio combines neurological care with oncology, reflecting broad expertise in disorders that affect the brain and nervous system.

A substantial part of the trial activity covers cardiovascular diseases, kidney disorders, and critical illness, including acute coronary syndrome, heart failure, hypertension, acute kidney injury, chronic kidney disease, and sepsis. These studies are designed to test better treatments, reduce complications, and improve care for seriously ill patients.

• Therapies for heart failure, coronary disease, and vascular conditions
• Renal-focused studies in nephropathy, transplant-related complications, and kidney injury
• Critical care research for sepsis, shock, and severe respiratory failure

The research landscape here also includes efforts to improve outcomes in patients with multi-organ failure and to support recovery after major illness or surgery.

Trials in respiratory tract diseases, digestive system diseases, and metabolic disorders cover conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, hepatocellular carcinoma, inflammatory bowel disease, diabetes, and obesity. The purpose is to evaluate new therapies, improve disease control, and explore better ways to manage long-term complications.

• Respiratory studies in chronic and severe lung disease
• Digestive system research in liver, biliary, and bowel conditions
• Metabolic studies addressing diabetes, lipid disorders, and weight-related disease

This broad portfolio shows a strong interest in conditions that often require long-term monitoring and individualized treatment strategies.

The site supports research in congenital and hereditary diseases, pediatric cancers, rare blood disorders, and transplantation. Areas of interest include Duchenne muscular dystrophy, spinal muscular atrophy, beta-thalassemia, sickle cell disease, neuroblastoma, and kidney and liver transplantation. These trials aim to improve treatment safety, long-term outcomes, and care for patients with uncommon or complex conditions.

• New therapies for rare genetic and neuromuscular diseases
• Pediatric oncology studies for difficult-to-treat childhood cancers
• Transplant research focused on rejection prevention and post-transplant complications

The breadth of this work highlights the center’s role in studying specialized conditions that often have limited treatment options.